Repetitive Transcranial Magnetic Stimulation (rTMS) Self-Referential Processing (rTMS-SRP)

Inclusion Criteria: 1. Between 18 and 45 years of age 2. Within 10 years of illness onset as defined by entry into treatment for psychotic symptoms 3. Able to give informed consent 4. Willing and able to adhere to the study schedule 5. Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (SCID-5) diagnosis of schizophrenia or schizoaffective disorder 6. Clinical stability as defined by: * Clinical Global Impression scale - Severity (CGI-S) score of less than or equal to 4 (moderately ill) at baseline AND * No exacerbation of their illness within 4 weeks prior to randomization, leading to an intensification of psychiatric care in the opinion of the investigator. Examples of intensification of care include, but are not limited to: inpatient hospitalization, day/partial hospitalization, outpatient crisis management, or psychiatric treatment in an emergency room AND * Antipsychotic treatment stability for at least 4 weeks prior to randomization (no change in antipsychotic dosing or addition of any new antipsychotic medication). Exclusion Criteria: 1. Lifetime history of a seizure, excluding febrile seizures and those induced by substance withdrawal 2. First degree relative (that is, biological father, mother, brother, sister, or child) with idiopathic epilepsy or other seizure disorder 3. History of significant neurological illness (including stroke, central nervous system (CNS) infection with persistent neurologic deficit, or other event deemed significant by PI) 4. History of head trauma as defined by a loss of consciousness or a post-concussive syndrome 5. Pregnant or breast feeding 6. Known intelligence quotient (IQ) \< 70 based on subject report 7. Subjects with current acute, serious, or unstable medical conditions, including, but not limited to: inadequately controlled diabetes, asthma, chronic obstructive pulmonary disease (COPD), severe hypertriglyceridemia, recent cerebrovascular accidents, acute systemic infection or immunologic disease, unstable cardiovascular disorders, malnutrition, or hepatic, renal gastroenterological, respiratory, endocrine, neurologic, hematologic, or infectious diseases based on medical history or physical examination 8. Metallic objects planted in or near the head, including implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, transcutaneous electrical nerve stimulation (TENS) unit, ventriculoperitoneal shunt, or cochlear implants 9. Contraindications to MRI or otherwise unable to tolerate MRI procedures 10. History of electroconvulsive therapy 11. Subjects taking clozapine 12. Subjects who have participated in a clinical trial with any pharmacological treatment intervention for which they received study-related medication in the 4 weeks prior to randomization 13. Subjects considered a high risk for suicidal acts - active suicidal ideation as determined by clinical interview OR any suicide attempt in 90 days prior to screening 14. Current SCID-5 diagnosis of substance use disorder (excluding nicotine or caffeine) 15. Subjects who require concomitant treatment with prohibited medication, as specified in Attachment 2